期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 112, 期 2, 页码 164-172出版社
WILEY
DOI: 10.1002/jso.23982
关键词
adrenocortical carcinoma; prognosis; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio
资金
- NCI NIH HHS [K08 CA168999] Funding Source: Medline
BackgroundThe systemic inflammatory response may be associated with tumor progression. We sought to analyze the impact of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) on recurrence-free survival (RFS) and disease-specific survival (DSS) among patients who underwent surgery for adrenocortical carcinoma (ACC). MethodsPatients undergoing surgery for ACC were identified from a multi-center database. Cut-off values of 5 and 190 were defined as elevated NLR and PLR, respectively, and long-term outcome was assessed. ResultsAmong 84 patients with ACC, 29 (34.%) had NLR>5 while 32 (40.5%) had PLR>190. NLR and PLR were associated with larger tumors (NLR>5: 5cm, 0% vs. >5cm, 39.7%; PLR>190: 5cm, 0% vs. >5cm, 45.7%), as well as need to resect of other organs (NLR>5: other organ resected 48.8% vs. not resected 20.9%; PLR>190: other organ resected 25.0% vs. not resected 56.4%)(all P<0.05). Five-year RFS was associated with an elevated NLR (NLR5, 14.2% vs. NLR>5, 10.5%) and PLR (PLR190: 19.4% vs. PLR>190: 5.2%) (both P<0.05). On multivariate survival analyses, PLR remained a predictor of RFS (HR 1.72), while NLR was associated with both DSS (HR 2.21) and RFS (HR 1.99) (both P<0.05). ConclusionsImmune markers such as NLR and PLR may be useful to stratify patients with regards to prognosis following surgery for ACC. J. Surg. Oncol. 2015 111:164-172. (c) 2015 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据